A Randomized, Double-Blind, Placebo-Controlled Trial Protocol Using the Fuzhengxiaoliu Patch for the Management of Primary Liver Cancer Pain

被引:0
|
作者
Li, Siman [1 ]
Wang, Binding [1 ]
Deng, Jiayao [2 ]
Li, Haiyan [2 ]
Wu, Yong [3 ]
Fang, Yu [2 ]
Yan, Bohua [2 ]
Chen, Yu [2 ]
机构
[1] Chengdu Univ TCM, Sch Clin Med, Chengdu, Sichuan, Peoples R China
[2] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China
[3] Chengdu Zhongxiang Pharmaceut Technol Co Ltd, Chengdu, Sichuan, Peoples R China
来源
JOURNAL OF PAIN RESEARCH | 2025年 / 18卷
关键词
primary liver cancer; traditional Chinese medicine; Chinese herb; cancer pain management; randomized controlled trial; MECHANISMS;
D O I
10.2147/JPR.S500305
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Chronic pain strongly affects the quality of life of patients with liver cancer pain. Safe and effective management of cancer- related pain is a worldwide challenge. Traditional Chinese medicine (TCM) has rich clinical experience in the treatment of cancer pain. The Fuzhengxiaoliu patch (FZXLP) is a compound TCM with the effects of detoxification and pain relief and has shown great efficacy in the treatment of patients with liver cancer, but high-quality clinical research that provides research-based evidence is lacking. We designed a randomized, double-blind, placebo-controlled trial to explore and evaluate the efficacy of FZXLP for the treatment of liver cancer pain. Methods: This is a prospective, randomized, double-blind, placebo-controlled trial. The trial will enrol 72 participants with primary liver cancer with cancer pain (damp-heat stagnation and toxin and blood stasis syndrome). The primary objective is to measure the reduction in pain using FZXLP in combination with tegafur, gimeracil and oteracil potassium capsule (S-1) compared to the placebo group with S-1. Pain will be measured by the number of opioids used, Chinese versions of the numerical rating scale (NRS), pain relief rate and number of breakthrough cases of cancer pain (BTcP). The secondary objectives include response evaluation criteria in solid tumors (RECIST), tumor markers, TCM syndrome scores, weight, functional assessment of cancer therapy-hepatobiliary (FACT-Hep) questionnaire scores, and self-rating anxiety scale scores. Adverse events (AEs) will be recorded throughout the study. Discussion: This study integrated TCM with clinical research to assess the efficacy and safety of the addition of FZXLP in the treatment of primary liver cancer pain. Trial registration: Chinese clinical trial registry, ChiCTR2300076951, Registered on October 25, 2023. https://www.chictr.org.cn/ showproj.html?proj=209608.
引用
收藏
页码:33 / 42
页数:10
相关论文
共 50 条
  • [31] LANREOTIDE REDUCES THE VOLUME OF POLYCYSTIC LIVER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    van Keimpema, Loes
    Nevens, Frederik
    Vanslembrouck, Ragna
    van Oijen, Martijn G.
    Hoffmann, Aswin L.
    Dekker, Helena M.
    De Man, Robert A.
    Drenth, Joost P.
    HEPATOLOGY, 2009, 50 (04) : 328A - 328A
  • [32] Vitamin D supplementation for primary dysmenorrhea: a double-blind, randomized, placebo-controlled trial
    Rahnemaei, Fatemeh Alsadat
    Gholamrezaei, Ali
    Afrakhteh, Maryam
    Zayeri, Farid
    Vafa, Mohammad Reza
    Rashidi, Arian
    Ozgoli, Giti
    OBSTETRICS & GYNECOLOGY SCIENCE, 2021, 64 (04) : 353 - 363
  • [33] A double-blind, placebo-controlled, Randomized trial of Bupropion for smoking cessation in primary care
    Fossati, Roldano
    Apolone, Giovanni
    Negri, Emanuele
    Compagnoni, Anna
    La Vecchia, Carlo
    Mangano, Simone
    Clivio, Luca
    Garattini, Silvio
    ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (16) : 1791 - 1797
  • [34] Lanreotide reduces the volume of polycystic liver: A randomized, double-blind, placebo-controlled trial
    Van Keimpema, Loes
    Nevens, Frederik
    Vanslembrouck, Ragna
    Van Oijen, Martijn G. H.
    Hoffmann, Aswin L.
    Dekker, Helena M.
    De Man, Robert A.
    Drenth, Joost P. H.
    GASTROENTEROLOGY, 2009, 137 (05) : 1661 - 1668
  • [35] Prophylactic fluconazole in liver transplant recipients - A randomized, double-blind, placebo-controlled trial
    Winston, DJ
    Pakrasi, A
    Busuttil, RW
    ANNALS OF INTERNAL MEDICINE, 1999, 131 (10) : 729 - +
  • [36] Effect of Pain Education and Exercise on Pain and Function in Chronic Achilles Tendinopathy: Protocol for a Double-Blind, Placebo-Controlled Randomized Trial
    Post, Andrew A.
    Rio, Ebonie K.
    Sluka, Kathleen A.
    Moseley, G. Lorimer
    Bayman, Emine O.
    Hall, Mederic M.
    Netto, Cesar de Cesar
    Wilken, Jason M.
    Danielson, Jessica F.
    Chimenti, Ruth
    JMIR RESEARCH PROTOCOLS, 2020, 9 (11):
  • [37] Adenosine and ATP in the management of postoperative pain: a randomised, double-blind, placebo-controlled trial
    Pieter, C. Dagnelie
    Wijckmans, N. E. G.
    Elzinga, L.
    Willems, R.
    Theunissen, H. M. S.
    Vossen, C.
    Marcus, M. A.
    van Suijlekom, J. A.
    PURINERGIC SIGNALLING, 2008, 4 : S121 - S122
  • [38] Antibiotic prophylaxis in the management of vesicoureteric reflux: a randomized double-blind placebo-controlled trial
    Hari, Pankaj
    Hari, Smriti
    Sinha, Aditi
    Kumar, Rakesh
    Kapil, Arti
    Pandey, Ravindra Mohan
    Bagga, Arvind
    PEDIATRIC NEPHROLOGY, 2015, 30 (03) : 479 - 486
  • [39] Topiramate for the management of methamphetamine dependence: a pilot randomized, double-blind, placebo-controlled trial
    Rezaei, Farzin
    Ghaderi, Ebrahim
    Mardani, Roya
    Hamidi, Seiran
    Hassanzadeh, Kambiz
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 (03) : 282 - 289
  • [40] Antibiotic prophylaxis in the management of vesicoureteric reflux: a randomized double-blind placebo-controlled trial
    Pankaj Hari
    Smriti Hari
    Aditi Sinha
    Rakesh Kumar
    Arti Kapil
    Ravindra Mohan Pandey
    Arvind Bagga
    Pediatric Nephrology, 2015, 30 : 479 - 486